Camzyos (mavacamten) / BMS - LARVOL DELTA

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy. (PubMed, Biomedicines) - "In summary, cardiac myosin inhibitors are a promising class of disease-modifying drugs for HCM with proven short-term safety and efficacy, but limited data are available to fully determine their long-term effects and efficacy in diverse patient populations. Ongoing research is necessary to further explore and define their role in HCM management."

Journal • Review • Cardiomyopathy • Cardiovascular • Heart Failure • Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy in the real world: bridging guidelines and clinical practice (ESC-WCC 2025) - "Explore current strategies for risk stratification and evidence-based approaches to prevent sudden cardiac death in HCM patients, with a focus on real-world applications. Review best practices for the long-term management and follow-up of patients with oHCM treated with mavacamten through clinical case discussions, enhancing clinical decision-making skills."

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Beyond the obvious: decoding the diagnostic dilemmas in hypertrophic cardiomyopathy (ESC-WCC 2025) - "Explore the critical role of echocardiography in the differential diagnosis of HCM and discuss the potential applications and benefits of AI tools in enhancing diagnostic accuracy. Review best practices for the management of symptomatic oHCM with mavacamten through clinical case discussions and understand long-term management and follow-up strategies for oHCM patients."

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

ODYSSEY-HCM: Mavacamten in nHCM (ESC-WCC 2025) - No abstract available

Cardiovascular

Echocardiographic changes in nonobstructive hypertrophic cardiomyopathy patients treated with mavacamten: A sub-study of the ODYSSEY-HCM trial (ESC-WCC 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Cardiac biomarkers on mavacamten in nonobstructive HCM: Sub-study of the ODYSSEY-HCM trial (ESC-WCC 2025) - No abstract available

Biomarker • Cardiovascular • Non-obstructive Hypertrophic Cardiomyopathy

Mavacamten real-world experience: insights from the Dutch HCM Network. (ESC-WCC 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiovascular • Heart Failure

Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy (ESC-WCC 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Real-world symptom and echocardiographic improvement in obstructive HCM patients treated with mavacamten: evidence of favorable disease modification (ESC-WCC 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Effect of mavacamten on left ventricular myocardial volume, strain and tissue characteristics in patients with hypertrophic cardiomyopathy (ESC-WCC 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten in hypertrophic cardiomyopathy: use of accessible functional testing to examine real-world effectiveness (ESC-WCC 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials (ESC-WCC 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Utilising mavacamten to mitigate post TAVR suicide left ventricle risk in patient with concomitant severe aortic stenosis, hypertrophic obstructive cardiomyopathy, and severe coronary artery disease. (ESC-WCC 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Multicenter study on the effect of Mavacamten on pulmonary artery systolic pressure derived from echo-doppler in obstructive hypertrophic cardiomyopathy (ESC-WCC 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Electrocardiographic markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy (ESC-WCC 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Integrated efficacy and safety analysis of mavacamten monotherapy in patients with obstructive hypertrophic cardiomyopathy (ESC-WCC 2025) - No abstract available

Clinical • Monotherapy • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Emergency Alcohol Septal Ablation for Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy. (PubMed, JACC Case Rep) - "Emergency ASA is an effective, minimally invasive intervention for managing acute LVOTO in high-risk patients with HCM. Adjunctive use of mavacamten after ASA can further improve outcomes, highlighting the importance of combining procedural and pharmacologic therapies in managing high-risk HCM."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Effects of mavacamten on the cellular response to beta adrenergic and frequency dependent stress in an HFpEF mouse model (ESC-WCC 2025) - No abstract available

Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Real-world outcomes of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy: global evidence from COLLIGO-HCM (ESC-WCC 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Pharmacogenetics for mavacamten treatment individualization in patients with obstructive hypertrophic cardiomyopathy (ESC-WCC 2025) - No abstract available

Biomarker • Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Systematic evaluation of serial electrocardiographic changes in patients treated with mavacamten (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular

Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM (ESC-WCC 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

MavaEnEx: Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy (clinicaltrials.gov) - P=N/A | N=24 | Recruiting | Sponsor: Technical University of Munich

New trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Systematic Review of Clinical Trials on Mavacamten in Hypertrophic Cardiomyopathy. (PubMed, Heart Int) - "Although systolic dysfunction is a major safety risk that requires careful monitoring, mavacamten was generally well tolerated. Mavacamten offered a promising, non-invasive pharmacological therapy for patients with symptomatic oHCM, particularly for those who are not candidates for or who have failed conventional treatments."

Journal • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy. (PubMed, J Am Heart Assoc) - "Mavacamten is a safe and effective treatment for symptomatic left ventricular outflow obstruction in patients with obstructive hypertrophic cardiomyopathy resistant to previous advanced pharmacologic therapy, surgery, or alcohol septal ablation or who develop manifest left ventricular outflow obstruction after aortic valve replacement."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy